Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

DNHL1 Inhibitors

DNHL1 Inhibitors constitute a distinctive and specialized category within the realm of chemical compounds. These inhibitors exhibit a discernible structural framework, marked by specific chemical moieties and functional groups that define their interaction with biological entities. The primary target of these inhibitors is the DNHL1 protein, an essential player within the intricate network of cellular signaling pathways. Through a process that hinges on molecular recognition and selective binding, DNHL1 Inhibitors establish a unique connection with the DNHL1 protein, disrupting its native conformation and subsequent functionality. The DNHL1 protein is acknowledged for its significant contributions to diverse cellular processes, spanning from cellular growth and differentiation to responses to external stimuli. By interfacing with DNHL1, the inhibitors potentially impede its involvement in these multifaceted pathways. The intricacy of the cellular cascades regulated by DNHL1 amplifies the importance of its targeted modulation. DNHL1 Inhibitors are designed to navigate the intricate three-dimensional landscape of the protein, often acting upon specific pockets or regions crucial for its activity.

Mechanistically, the binding of DNHL1 Inhibitors to the DNHL1 protein can trigger a cascade of events. This interaction might lead to a distortion in the protein's tertiary structure, thereby hindering its capacity to engage with other cellular components. Alternatively, the inhibitors might obstruct the access of key molecules or substrates to the binding sites on the protein surface. These nuanced effects subsequently ripple through the cellular pathways, potentially altering cellular responses to various internal and external cues. The realm of DNHL1 Inhibitors represents a domain of active scientific inquiry and exploration. Researchers delve into the intricacies of these inhibitors' interactions with the DNHL1 protein, deciphering the precise molecular determinants that underlie their binding and inhibitory properties. Insights gained from these studies not only expand our fundamental understanding of cellular biology but also hold promise for broader applications in areas beyond the confines of this intricate protein network.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Tyrosine kinase inhibitor targeting BCR-ABL, used in chronic myeloid leukemia.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple kinases including RAF, VEGFR, and PDGFR, used in cancer.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for cancer.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Targets BCR-ABL and SRC family kinases, used in chronic myeloid leukemia.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor for breast cancer research.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Irreversible inhibitor of Bruton's tyrosine kinase (BTK), used in B-cell cancers.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, promotes apoptosis, used in chronic lymphocytic leukemia.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$210.00
$305.00
$495.00
10
(1)

PARP inhibitor, blocks DNA repair in BRCA-mutated cancers.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, halts cell cycle progression, used in breast cancer.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

Inhibits mutant BRAF V600E kinase, used in melanoma therapy.